Biosceptre is a biopharmaceutical company focused on the development of our BRiDGECAR™ system, which combines our nfP2X7-targeted technology with highly potent chimeric antigen receptor (CAR) T-cell therapy and multiple targeted antibodies. This system has the potential of delivering unprecedented outcomes to many types of cancer.
With Nobel prize-winning science leadership and renowned researchers, our work is founded on science from the University of Sydney. Biosceptre is headquartered in the UK and has research underway in Sydney, Australia.
Supported by the ongoing collaboration with global experts and major research institutes, Biosceptre continues to drive innovation and pioneer the future of multi-targeted CAR-T oncology therapeutics.